Welcome to our dedicated page for Integra LifeSciences Holdings news (Ticker: IART), a resource for investors and traders seeking the latest updates and insights on Integra LifeSciences Holdings stock.
Integra LifeSciences Holdings Corporation (NASDAQ: IART) is a global leader in medical technology, headquartered in Plainsboro, New Jersey. Established in 1989, Integra is dedicated to reducing uncertainty for surgeons, allowing them to focus on providing outstanding patient care. The company offers innovative solutions in various medical fields including orthopedic extremity surgery, neurosurgery, spine surgery, and reconstructive and general surgery.
Integra's diverse portfolio includes products for regenerative therapy, extremity orthopedics, and neurosurgical applications. Their orthopedic product line features devices and implants for spine, foot and ankle, hand and wrist, shoulder and elbow, tendon and peripheral nerve protection and repair, and wound repair. The company is also a key player in the neurosurgery market, offering a broad range of implants, devices, instruments, and systems used in neurosurgery, neuromonitoring, neurotrauma, and critical care.
Integra operates through two main segments: Codman Specialty Surgical and Tissue Technologies. The Codman Specialty Surgical segment generates the majority of the company's revenue, focusing on neurosurgical and surgical instrumentation. The Tissue Technologies segment covers regenerative and advanced wound care products.
With over 3,500 employees worldwide, Integra serves markets in Europe, the Asia-Pacific region, and other parts of the globe, although the bulk of its revenue comes from domestic sales. Recently, the company announced its second-quarter 2023 financial results, highlighting a total revenue of $381.3 million, a slight decline compared to the previous year, primarily due to a recall issue at their Boston manufacturing facility. Despite this, the company showed resilience with strong performances in certain product lines and updated their guidance for 2023 revenue and earnings per share.
Integra's recent acquisition of Acclarent, a leader in ENT procedures, for $275 million, showcases their ongoing commitment to expanding their product offerings and improving healthcare outcomes. This acquisition is expected to close by the second quarter of 2024 and will significantly bolster Integra's position in the ENT market.
Integra continues to develop and launch groundbreaking products such as the CereLink ICP Monitoring System for intracranial pressure monitoring and the MicroMatrix Flex, which addresses complex wound reconstruction needs. These innovations reflect Integra's dedication to advancing surgical, neurologic, and regenerative care standards.
For the latest updates and further information, visit www.integralife.com.
Integra LifeSciences Holdings Corporation has appointed Jan D. De Witte as its new President and CEO, succeeding Peter J. Arduini, who is moving to GE Healthcare. De Witte, who has over 30 years of global executive experience in healthcare and technology, previously served as CEO of Barco N.V. and held leading roles at GE. The board expressed confidence in De Witte's ability to drive innovation and stakeholder value. De Witte will officially join the company by the end of the year. This leadership transition comes as Integra aims to enhance its global impact in neurosurgery and regenerative tissue technologies.
Integra LifeSciences Holdings Corporation (NASDAQ: IART) will release its third quarter 2021 financial results on November 2, 2021, before the market opens. A conference call, hosted by management at 8:30 a.m. ET, will discuss the earnings. The call can be accessed at (888) 394-8218 with passcode 7732018, and a webcast will be available on the company’s website. A replay will be accessible until November 12, 2021. Integra specializes in regenerative tissue technologies and neurosurgical solutions, offering a wide range of medical products.
Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leader in medical technology, has announced its participation in two upcoming investor conferences. Carrie Anderson, the executive vice president and CFO, will present at the Wells Fargo 2021 Virtual Healthcare Conference on September 9, 2021, at 11:20 AM ET, and at the Morgan Stanley 19th Annual Global Healthcare Conference on September 13, 2021, at 1:15 PM ET. Interested parties can access the webcasts via the company’s website. Integra specializes in regenerative tissue technologies and neurosurgical solutions.
Integra LifeSciences (IART) reported Q2 2021 revenues of $390 million, a 50.8% increase year-over-year, driven by robust demand in neurosurgery and surgical instruments. GAAP earnings per diluted share rose to $0.41, compared to $(0.00) last year, while adjusted EPS also improved to $0.79. The company raised its full-year revenue guidance by $15 million to between $1,540 million and $1,550 million, and adjusted EPS guidance to $2.98 to $3.05. Cash flow from operations reached $91.3 million, marking a 176% increase.
Integra LifeSciences has announced positive results from a clinical study utilizing its PriMatrix Dermal Repair Scaffold for treating hard-to-heal diabetic foot ulcers (DFUs). Conducted with over 200 patients, the randomized controlled trial found that a single application of PriMatrix, combined with standard care, healed 60% of DFUs within 12 weeks, compared to 35% with standard care alone. This significant improvement highlights PriMatrix's potential for cost-effective treatment, addressing a major health issue affecting millions of diabetics in the U.S.
Integra LifeSciences (Nasdaq: IART) announced that its SurgiMend® Collagen Matrix for soft tissue reconstruction has been awarded an Innovative Technology contract by Vizient, Inc.. This recognition is based on recommendations from healthcare professionals and indicates the product's potential to enhance patient outcomes. SurgiMend is FDA-cleared for surgical repair and demonstrates low recurrence rates in complex abdominal wound reconstruction. The contract reflects SurgiMend's unique qualities that distinguish it from competitors, bolstering Integra's position in the healthcare market.
Integra LifeSciences Holdings Corporation (NASDAQ: IART) will release its second quarter 2021 financial results on July 28, 2021, before market open. The management team will host a conference call at 8:30 a.m. ET, accessible by dialing (800) 367-2403 and using passcode 3706513. A simultaneous webcast will be available on the company’s website. A replay will be accessible until August 7, 2021. Integra is a global leader in regenerative tissue technologies and neurosurgical solutions, providing a comprehensive portfolio of high-quality brands aimed at enhancing patient care.
Peter Arduini will serve as President and CEO of Integra LifeSciences through the end of 2021 before transitioning to a new role at GE Healthcare. The company acknowledges his 11 years of impactful leadership, during which it achieved significant growth and established itself in neurosurgery. A search for a qualified successor has commenced, with expectations to conclude by year-end. Arduini will ensure a seamless transition, maintaining the company's momentum. Integra is well-positioned strategically and financially for ongoing growth.
Integra LifeSciences Holdings Corporation (NASDAQ: IART) hosted an Investor Day, highlighting expectations for Q2 2021 revenues between $372 million and $378 million, and adjusted EPS between $0.63 and $0.67. The company reaffirmed full-year guidance of $1,525 million to $1,535 million in revenue and adjusted EPS of $2.86 to $2.93. Long-term targets include 5% to 7% organic revenue growth and double-digit adjusted EPS growth. The company aims for adjusted gross margins of 70-72% and adjusted EBITDA margins of 28-30% by 2023.
Integra LifeSciences Holdings Corporation (NASDAQ: IART) is set to host an Investor Day meeting on May 20, 2021, from 8:30 a.m. to approximately 12:30 p.m. U.S. Eastern Time. The event will be led by CEO Peter Arduini and the executive leadership team. Interested participants can preregister online and access a live webcast of the presentation on the company’s website. A replay will also be available post-event. Integra is recognized for its innovation in regenerative tissue technologies and neurosurgical solutions.
FAQ
What is the current stock price of Integra LifeSciences Holdings (IART)?
What is the market cap of Integra LifeSciences Holdings (IART)?
What does Integra LifeSciences Holdings Corp. specialize in?
Where is Integra LifeSciences headquartered?
What are the primary segments of Integra LifeSciences?
What recent acquisition was announced by Integra LifeSciences?
What are some of the key products offered by Integra LifeSciences?
How did Integra perform financially in the second quarter of 2023?
What is the purpose of Integra’s CereLink ICP Monitoring System?
How many employees does Integra LifeSciences have?
Which markets does Integra LifeSciences serve?
What is Integra’s strategy for growth in 2024?
